PBA
VRNA

Paradigm Biocapital Advisors’s Verona Pharma VRNA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-721,087
Closed -$10.4M – 42
2024
Q2 		$10.4M Buy
+721,087
New +$10.5M 0.4% 30
2023
Q4 		– Sell
-926,432
Closed -$15.1M – 37
2023
Q3 		$15.1M Buy
926,432
+32,571
+4% +$627K 1.02% 23
2023
Q2 		$18.9M Sell
893,861
-68,500
-7% -$1.46M 1.46% 27
2023
Q1 		$19.3M Buy
+962,361
New +$20.8M 1.83% 20

Other funds holding VRNA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Paradigm Biocapital Advisors's VRNA Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Verona Pharma (VRNA) in Q3 2024, closing a stake of 721,087 shares — an estimated $10.4M sold.

Paradigm Biocapital Advisors first reported a position in VRNA in Q1 2023 and held it in 4 quarters. The position peaked at $19.3M in Q1 2023. 150 funds tracked by Wall St. Rank hold VRNA as of Q3 2024.

  • Paradigm Biocapital Advisors reported no remaining Verona Pharma position as of Q3 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 721,087 Verona Pharma shares in Q3 2024, an estimated $10.4M.
  • Paradigm Biocapital Advisors first reported a position in Verona Pharma in Q1 2023 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's Verona Pharma position peaked at $19.3M in Q1 2023.
  • 150 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.